Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that as larger pharmaceutical companies retreat from the hospital antibiotics market, smaller pharmaceutical companies, such as Cubist, Vicuron, Basilea, and Novexel are poised to establish niches in this arena. According to the new DR Pipeline Report entitled Hospital Antibiotics Pipeline Analysis: Big Pharma's Retreat Creates Opportunities for Biotech, large pharmaceutical companies such as Roche, Wyeth, Pfizer, Johnson & Johnson, Merck, and GlaxoSmithKline have dominated the market but many of these companies have mature products that are facing recent or impending competition from generics.

"The large pharmaceutical companies have retreated from investing in early-stage antibiotics development and appear to be shifting toward a model of outlicensing preclinical drug candidates and inlicensing advanced-stage drug candidates from smaller companies," said Aaron Woolsey, Ph.D., analyst at Decision Resources. "Even though larger pharmaceutical companies and generics manufacturers will still dominate the hospital antibiotics drug market, new, innovative products developed by smaller pharmaceutical companies will, collectively, begin to command a growing share of the market."

About the Hospital Antibiotics Market

The hospital antibiotics market is comprised of drugs that treat infections that are acquired either in the hospital (hospital-acquired infections) or in the community (community-acquired infections) and are treated in a hospital-based setting. Hospital based-infections cause considerable morbidity and are of grave concern to both patients and clinicians.

About DR Pipeline Reports from Decision Resources

DR Pipeline Reports is a series of comprehensive reports that focuses on pharmaceutical and biotech company drug development and commercialization strategies. Geared toward business development decision makers in the pharmaceutical, biotech, and financial industries, the DR Pipeline Reports expose major players in a therapeutic market and, more importantly, shed light on the emerging players that could significantly impact the current market once their pipelines are launched.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Sales of Genentech/Roche/Chugai's Herceptin for the Treatment of Breast Cancer Will Nearly Triple by 2009

View Now